Close Menu

siRNA

Notably, the patent in dispute is part of the so-called Zamore IP family. Alnylam's top official earlier this year publicly dismissed a related US patent from the Zamore family as "not worth anything."

Life Technologies, Altogen Biosystems

The Phase I study is being conducted in the US and Israel with two patient subgroups — stratum I, which includes patients with chronic nerve atrophy and began dosing in March; and stratum II, which is enrolling patients with recent onset of NAION.

The siRNAs inhibited tumor necrosis factor-alpha, a pro-inflammatory cytokine implicated in a variety of inflammatory diseases, in the animals' colons and protected against ulcerative colitis, according to the paper.

The company noted that since it develops LNP formulations individually for each of its drug candidates, the delay in TKM-apoB will have "no impact" on any of its other drug programs or those of its collaboration partners, who include Roche and Pfizer.

The grants, which are focused on therapeutic applications of siRNAs, are collectively worth more than $800,000.

Earlier this summer, the company completed a phase Ia trial, finding the agent to be safe and well-tolerated in healthy volunteers.

Cellecta

The collaboration brings together Ariadne, Cellecta, and the Roswell Park Cancer Institute to develop "a better understanding of the mechanisms of prostate cancer that result in novel targets and biomarkers."

According to a company official, future deals, as with the one with Nitto Denko, will be driven by Quark's freedom to operate in the siRNA drugs space.

Pages

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.